Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vaccine shield newborns from a deadly bacterial infection?

NCT ID NCT04596878

Completed ⭐️ VACCINE ⭐️ Sponsor: Minervax ApS Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests an experimental vaccine called GBS-NN/NN2 against Group B Streptococcus (GBS), a bacteria that can cause serious infections in newborns. The trial includes pregnant women both with and without HIV, giving two doses between 26 and 30 weeks of pregnancy. Researchers will monitor safety and immune responses in mothers and their babies for a year after birth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a recombinant protein vaccine against Group B Streptococcus called GBS-NN/NN2, given with an adjuvant
What this could lead to
If successful, this vaccine could prevent life-threatening Group B Strep infections in newborns, especially in areas with high HIV rates.
What could go wrong
This is a Phase 2 trial, so it is still early. The vaccine may not produce enough immunity or could have unexpected side effects in mothers or babies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GROUP B STREPTOCOCCAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease streptococcal infection group B streptococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GROUP B STREPTOCOCCAL INFECTION

Contacts and locations

Locations

  • Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital

    Johannesburg, South Africa

  • MUJHU Research Collaboration/MUJHU Care Ltd, Kawempe National Referral Hospital

    Kawempe, Uganda

  • University of the Witwatersrand, Johannesburg (Respiratory and Meningeal Pathogens Research unit)

    Johannesburg, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.